SG10201500620PA - Compounds, compositions and methods for protecting brain health in neurodegenerative disorders - Google Patents
Compounds, compositions and methods for protecting brain health in neurodegenerative disordersInfo
- Publication number
- SG10201500620PA SG10201500620PA SG10201500620PA SG10201500620PA SG10201500620PA SG 10201500620P A SG10201500620P A SG 10201500620PA SG 10201500620P A SG10201500620P A SG 10201500620PA SG 10201500620P A SG10201500620P A SG 10201500620PA SG 10201500620P A SG10201500620P A SG 10201500620PA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- compounds
- methods
- neurodegenerative disorders
- brain health
- Prior art date
Links
- 230000036995 brain health Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22837409P | 2009-07-24 | 2009-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201500620PA true SG10201500620PA (en) | 2015-03-30 |
Family
ID=43499678
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012004776A SG178086A1 (en) | 2009-07-24 | 2010-07-23 | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| SG10201500620PA SG10201500620PA (en) | 2009-07-24 | 2010-07-23 | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012004776A SG178086A1 (en) | 2009-07-24 | 2010-07-23 | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8933217B2 (en) |
| EP (2) | EP2456772A4 (en) |
| JP (1) | JP5816171B2 (en) |
| CN (1) | CN102762573B (en) |
| AU (3) | AU2010275476B2 (en) |
| BR (1) | BR112012002183A2 (en) |
| CA (1) | CA2768963C (en) |
| IL (1) | IL217703A (en) |
| MX (1) | MX364173B (en) |
| MY (1) | MY159856A (en) |
| NZ (1) | NZ598290A (en) |
| RU (1) | RU2576032C2 (en) |
| SG (2) | SG178086A1 (en) |
| UA (1) | UA108856C2 (en) |
| WO (1) | WO2011011721A2 (en) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013335A2 (en) * | 2001-08-03 | 2003-02-20 | Vega Research Lab, Llc | Method and apparatus for determining metabolic factors from an electrocardiogram |
| BRPI0813770B1 (en) | 2007-06-26 | 2018-05-08 | N.V. Nutricia | use of a composition for the manufacture of a composition for improving and / or treating and / or preventing impaired delayed return function of an individual and, for improving memory and / or treating or preventing impaired memory function. |
| CN102123613B (en) * | 2008-09-02 | 2013-09-25 | 高砂香料工业株式会社 | Flavor improving agent |
| US9872850B2 (en) * | 2010-12-23 | 2018-01-23 | Amazentis Sa | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders |
| WO2013066152A1 (en) | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
| WO2013066151A1 (en) | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Improving recognition |
| AU2012361496A1 (en) * | 2011-12-27 | 2014-07-24 | Morishita Jintan Co., Ltd. | Maillard reaction inhibitor |
| WO2013160896A1 (en) | 2012-04-25 | 2013-10-31 | Hadasit Medical Research Services And Development Ltd. | Pomegranate oil for preventing and treating neurodegenerative diseases |
| CA3127211A1 (en) * | 2012-06-27 | 2014-01-03 | Amazentis Sa | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof |
| CN104703615A (en) * | 2012-09-13 | 2015-06-10 | 森下仁丹株式会社 | Sirtuin gene potentiator, and pharmaceutical product, cosmetic product, and food product using same |
| EP3074028B1 (en) * | 2013-11-27 | 2022-04-06 | Research Foundation Of The City University Of New York | Activity enhancing curcumin compositions and methods of use |
| EP3087065B1 (en) | 2013-12-23 | 2020-01-22 | Amazentis SA | Synthesis of urolithins |
| WO2015171597A1 (en) | 2014-05-05 | 2015-11-12 | 3D Glass Solutions, Inc. | 2d and 3d inductors antenna and transformers fabricating photoactive substrates |
| WO2016014927A2 (en) | 2014-07-24 | 2016-01-28 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| KR102629310B1 (en) | 2015-03-09 | 2024-01-24 | 더블유.알. 그레이스 앤드 캄파니-콘. | Crystal form of nicotinamide riboside |
| WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
| WO2017021974A2 (en) * | 2015-08-31 | 2017-02-09 | Laila Pharmaceuticals Pvt. Ltd. | Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts |
| US10070533B2 (en) | 2015-09-30 | 2018-09-04 | 3D Glass Solutions, Inc. | Photo-definable glass with integrated electronics and ground plane |
| WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
| JP7182837B2 (en) * | 2015-12-24 | 2022-12-05 | アマゼンティス エスアー | Compositions containing nicotinamide riboside and urolithins |
| BR112018013757B1 (en) | 2016-01-11 | 2021-11-09 | The Procter & Gamble Company | METHOD FOR THE TREATMENT OF A SKIN CONDITION AND COMPOSITIONS FOR IT |
| JP7071609B2 (en) | 2016-02-25 | 2022-05-19 | スリーディー グラス ソリューションズ，インク | Capacitor array for manufacturing 3D capacitors and photoactive substrates |
| US11161773B2 (en) | 2016-04-08 | 2021-11-02 | 3D Glass Solutions, Inc. | Methods of fabricating photosensitive substrates suitable for optical coupler |
| RU2019108100A (en) | 2016-08-22 | 2020-09-22 | Элизиум Хелт, Инк. | COMPOSITIONS OF NICOTINAMIDE RIBOSIDE AND PTEROSTILBENE AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES |
| CN106728015A (en) * | 2016-12-07 | 2017-05-31 | 孟光 | A kind of Chinese medicine preparation for nerve degenerative diseases and preparation method thereof |
| WO2018140383A1 (en) * | 2017-01-24 | 2018-08-02 | Leal Jesus | N-acetyle cysteine based compositions |
| WO2018162651A1 (en) | 2017-03-08 | 2018-09-13 | Amazentis Sa | Methods for improving mitophagy in subjects |
| US10946041B2 (en) * | 2017-03-27 | 2021-03-16 | Patrece Frisbee | Methods, compounds, and solutions for neurotransmitter restoration in mammals |
| JP7150342B2 (en) | 2017-04-28 | 2022-10-11 | スリーディー グラス ソリューションズ，インク | RF circulator |
| CN110785161B (en) | 2017-06-23 | 2023-06-20 | 宝洁公司 | Compositions and methods for improving the appearance of skin |
| JP6995891B2 (en) | 2017-07-07 | 2022-01-17 | スリーディー グラス ソリューションズ，インク | 2D and 3D RF centralized device for RF systems in packaged photoactive glass substrates |
| US10272107B2 (en) * | 2017-09-05 | 2019-04-30 | Kenneth O. Russell | Method for treating inflammatory brain disorders and traumatic brain injury |
| WO2019118761A1 (en) | 2017-12-15 | 2019-06-20 | 3D Glass Solutions, Inc. | Coupled transmission line resonate rf filter |
| CN112020363A (en) | 2017-12-22 | 2020-12-01 | 益力舒健康公司 | Crystalline forms of nicotinamide riboside chloride |
| JP7226832B2 (en) | 2018-01-04 | 2023-02-21 | スリーディー グラス ソリューションズ，インク | Impedance-matching conductive structures for high-efficiency RF circuits |
| KR102145746B1 (en) | 2018-04-10 | 2020-08-19 | 3디 글래스 솔루션즈 인코포레이티드 | RF integrated power conditioning capacitor |
| US20210236572A1 (en) * | 2018-05-08 | 2021-08-05 | Laila Nutraceuticals | Synergistic herbal compositions for testosterone boosting |
| WO2019231947A1 (en) | 2018-05-29 | 2019-12-05 | 3D Glass Solutions, Inc. | Low insertion loss rf transmission line |
| WO2020010036A1 (en) | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
| JP7053084B2 (en) | 2018-09-17 | 2022-04-12 | スリーディー グラス ソリューションズ，インク | Highly efficient compact slotted antenna with ground plane |
| JP7241433B2 (en) | 2018-12-28 | 2023-03-17 | スリーディー グラス ソリューションズ，インク | Heterogeneous Integration for RF, Microwave and MM Wave Systems on Photoactive Glass Substrates |
| WO2020139955A1 (en) | 2018-12-28 | 2020-07-02 | 3D Glass Solutions, Inc. | Annular capacitor rf, microwave and mm wave systems |
| WO2020172262A1 (en) * | 2019-02-19 | 2020-08-27 | James Janine | Chromium composition and methods thereof |
| WO2020206323A1 (en) | 2019-04-05 | 2020-10-08 | 3D Glass Solutions, Inc. | Glass based empty substrate integrated waveguide devices |
| CA3136642C (en) | 2019-04-18 | 2023-01-03 | 3D Glass Solutions, Inc. | High efficiency die dicing and release |
| CN111848725B (en) * | 2019-04-30 | 2023-01-13 | 首都医科大学 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl basic amino acid |
| CN111848726B (en) * | 2019-04-30 | 2022-06-24 | 首都医科大学 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl aromatic amino acid |
| CN111848727B (en) * | 2019-04-30 | 2022-04-22 | 首都医科大学 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl nonpolar amino acid |
| CN111848723B (en) * | 2019-04-30 | 2022-04-22 | 首都医科大学 | Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formylmethionine and proline |
| CN110613721B (en) * | 2019-09-23 | 2021-11-16 | 中国人民解放军第四军医大学 | New application of corilagin in preparing medicine for resisting sleep deprivation injury |
| WO2021211855A1 (en) | 2020-04-17 | 2021-10-21 | 3D Glass Solutions, Inc. | Broadband inductor |
| WO2021247496A1 (en) | 2020-06-01 | 2021-12-09 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| WO2022140536A1 (en) * | 2020-12-24 | 2022-06-30 | Natreon, Inc. | Neuroprotective phyllanthus emblica-containing compositions and methods |
| KR20230153533A (en) | 2021-01-27 | 2023-11-06 | 반드리아 에스에이 | Urolithin derivatives and methods of use thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL241315A (en) | 1958-07-18 | |||
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GR79615B (en) | 1982-10-08 | 1984-10-31 | Glaxo Group Ltd | |
| DK163640C (en) | 1985-07-30 | 1992-08-17 | Glaxo Group Ltd | DEVICE FOR ADMINISTRATING MEDICINES |
| US5236940A (en) * | 1988-12-15 | 1993-08-17 | Rhone-Poulenc Sante | Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation |
| JPH05963A (en) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| GB9808796D0 (en) | 1998-04-24 | 1998-06-24 | Rowett Research Services Limit | Antithrombotic agents |
| US6423365B1 (en) | 1998-12-11 | 2002-07-23 | Board Of Trustees Of Michigan State University | Method and compositions producing cherry derived products |
| US6194469B1 (en) | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
| US6676978B1 (en) | 1999-02-16 | 2004-01-13 | Board Of Trustees Of Michigan State University | Method and compositions for producing berry derived products |
| US7611738B2 (en) | 2005-05-24 | 2009-11-03 | Pom Wonderful, Llc | Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof |
| WO2001054516A1 (en) | 2000-01-28 | 2001-08-02 | Michigan State University | Method for inhibiting a tumor |
| JP4853936B2 (en) | 2000-08-21 | 2012-01-11 | ザ ジェネラル ホスピタル コーポレイション | Diagnosis of neurodegenerative condition |
| US20050059743A1 (en) | 2000-11-01 | 2005-03-17 | Sention, Inc. | Methods for treating mild cognitive impairment and alzheimer's disease |
| US20050165090A1 (en) | 2004-01-23 | 2005-07-28 | Kemberling J. K. | Polyphenols as an intravesical agent for the prevention of transitional cell tumor implantation |
| WO2005089066A2 (en) * | 2004-03-23 | 2005-09-29 | Rimonest Ltd. | Pharmaceutical compositions, methods of formulation thereof and methods of use thereof |
| DK1734949T3 (en) | 2004-03-24 | 2015-08-24 | Univ California | Remediation of ellagitannins |
| US20080214656A1 (en) | 2004-08-23 | 2008-09-04 | Neurogenex Co., Ltd. | Compounds With Diphenoyl-Structure For the Treatment of Immune Diseases |
| CA2601777A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| GB0502985D0 (en) | 2005-02-14 | 2005-03-16 | Provexis Ltd | Therapeutic uses of tomato extracts |
| AU2006247244B2 (en) | 2005-05-17 | 2012-05-17 | Satori Pharmaceuticals, Inc. | Compounds useful for treating neurodegenerative disorders |
| US20070036873A1 (en) | 2005-07-27 | 2007-02-15 | Shibnath Ghosal | Method of treatment or management of stress |
| ES2617061T3 (en) | 2006-04-11 | 2017-06-15 | Cognoptix, Inc | Eye image processing |
| GB0610790D0 (en) | 2006-06-02 | 2006-07-12 | Provexis Natural Products Ltd | Therapeutic uses of tomato extracts |
| WO2008080162A2 (en) | 2006-12-22 | 2008-07-03 | The Johns Hopkins University | Anti-cholesterolemic compounds and methods of use |
| EP2033526A1 (en) * | 2007-09-07 | 2009-03-11 | Probelte Pharma, S.A. | Nutritional products comprising pomegranate extracts containing ellagitannins and their use |
| JP2009102288A (en) * | 2007-10-19 | 2009-05-14 | Harunire Bio Kenkyusho:Kk | Fat accumulation inhibitor |
-
2010
- 2010-07-23 CN CN201080042939.4A patent/CN102762573B/en not_active Expired - Fee Related
- 2010-07-23 NZ NZ598290A patent/NZ598290A/en not_active IP Right Cessation
- 2010-07-23 MY MYPI2012000328A patent/MY159856A/en unknown
- 2010-07-23 JP JP2012521844A patent/JP5816171B2/en active Active
- 2010-07-23 BR BR112012002183A patent/BR112012002183A2/en not_active Application Discontinuation
- 2010-07-23 CA CA2768963A patent/CA2768963C/en not_active Expired - Fee Related
- 2010-07-23 RU RU2012106214/15A patent/RU2576032C2/en not_active IP Right Cessation
- 2010-07-23 MX MX2012001010A patent/MX364173B/en active IP Right Grant
- 2010-07-23 WO PCT/US2010/043107 patent/WO2011011721A2/en active Application Filing
- 2010-07-23 UA UAA201202090A patent/UA108856C2/en unknown
- 2010-07-23 EP EP10802978A patent/EP2456772A4/en not_active Withdrawn
- 2010-07-23 US US12/842,750 patent/US8933217B2/en active Active
- 2010-07-23 SG SG2012004776A patent/SG178086A1/en unknown
- 2010-07-23 EP EP16201224.9A patent/EP3202399A1/en not_active Withdrawn
- 2010-07-23 SG SG10201500620PA patent/SG10201500620PA/en unknown
- 2010-07-23 AU AU2010275476A patent/AU2010275476B2/en not_active Ceased
-
2012
- 2012-01-24 IL IL217703A patent/IL217703A/en not_active IP Right Cessation
-
2014
- 2014-12-29 US US14/584,581 patent/US9980980B2/en active Active
-
2015
- 2015-10-21 AU AU2015246090A patent/AU2015246090B2/en not_active Ceased
-
2017
- 2017-12-14 AU AU2017276266A patent/AU2017276266A1/en not_active Abandoned
-
2018
- 2018-05-29 US US15/991,551 patent/US20190000867A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012002183A2 (en) | 2016-05-31 |
| RU2576032C2 (en) | 2016-02-27 |
| JP2013500266A (en) | 2013-01-07 |
| RU2012106214A (en) | 2013-08-27 |
| WO2011011721A2 (en) | 2011-01-27 |
| EP2456772A2 (en) | 2012-05-30 |
| US8933217B2 (en) | 2015-01-13 |
| CN102762573A (en) | 2012-10-31 |
| AU2010275476A1 (en) | 2012-03-15 |
| MX2012001010A (en) | 2012-06-01 |
| JP5816171B2 (en) | 2015-11-18 |
| AU2010275476B2 (en) | 2015-07-23 |
| NZ598290A (en) | 2014-12-24 |
| EP2456772A4 (en) | 2013-02-27 |
| EP3202399A1 (en) | 2017-08-09 |
| IL217703A (en) | 2016-05-31 |
| US9980980B2 (en) | 2018-05-29 |
| IL217703A0 (en) | 2012-03-29 |
| MX364173B (en) | 2019-04-15 |
| AU2015246090B2 (en) | 2017-09-14 |
| AU2017276266A1 (en) | 2018-01-18 |
| CN102762573B (en) | 2015-09-16 |
| UA108856C2 (en) | 2015-06-25 |
| SG178086A1 (en) | 2012-03-29 |
| AU2015246090A1 (en) | 2015-11-05 |
| CA2768963A1 (en) | 2011-01-27 |
| MY159856A (en) | 2017-02-15 |
| US20110065662A1 (en) | 2011-03-17 |
| WO2011011721A9 (en) | 2011-06-09 |
| US20190000867A1 (en) | 2019-01-03 |
| US20150196577A1 (en) | 2015-07-16 |
| CA2768963C (en) | 2019-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL217703A0 (en) | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders | |
| HK1174064A1 (en) | Methods and compositions for cell-proliferation-related disorders | |
| EP2406389A4 (en) | Methods and compositions for cell-proliferation-related disorders | |
| EP2170309A4 (en) | Methods and compositions for treating disorders | |
| EP2176283A4 (en) | Methods and compositions for treating brain diseases | |
| EP2461819A4 (en) | Methods and compositions for treating trinucleotide repeat disorders | |
| IL253293A0 (en) | Desferrioxamine-metal complexes for the treatment of immune-related disorders | |
| IL209216A (en) | Compositions for preventing and treating neurodegenerative diseases | |
| HK1206590A1 (en) | New compositions for treating cmt and related disorders | |
| EP2271358A4 (en) | Neurodegenerative disorders | |
| PL2214683T3 (en) | Unit dosage for brain health | |
| EP2429584A4 (en) | Methods and compositions for treatment | |
| EP2550361A4 (en) | Compositions and methods for treating neurological disorders | |
| HK1169115A1 (en) | Therapeutic agent for motor disorders | |
| HK1171379A1 (en) | Composition for improving brain function and method for improving brain function | |
| EP2491019A4 (en) | Methods and compositions for panic disorders | |
| EP2515925A4 (en) | Compositions and methods for preventing and treating diseases and environmentally induced health disorders | |
| EP2347711A4 (en) | Device for creating database of alternative normal brain | |
| EP2219650A4 (en) | Compositions and methods for treating fibroproliferative disorders | |
| EP2237777A4 (en) | Compositions and methods for treating neurodegenerative diseases | |
| IL207906A0 (en) | Treatment for ocular-related disorders | |
| EP2501672A4 (en) | Compositions and methods for treating hyperproliferative disorders | |
| EP2103304A4 (en) | Composition for improving brain function | |
| EP2278982A4 (en) | Compositions and methods for treating neurodegenerative diseases | |
| IL218160A0 (en) | Desferrioxamine-metal complexes for the treatment of immune-related disorders |